SEC Form 4 · accession 0001213900-17-008982

ORAMED PHARMACEUTICALS INC. · ORMP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 17, 2017

Accepted (ET)

Aug 21, 2017 · 1:56 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001176309

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 17, 2017	M	112,613	$3.7656	A	1,299,436	I	By Regals Fund LP

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant (right to buy)^F2,F3	$3.7656	Aug 17, 2017	M	112,613	D	Aug 28, 2012	Aug 28, 2017	Common Stock	112,613	0	I

F1Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein.
F2The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
F3The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.